PA8.F Paion AG (XETRA) up 87.79% intraday 24 Mar 2026: catalyst may be short-term

We saw PA8.F stock jump 87.79% intraday to €0.08 on XETRA on 24 Mar 2026. The move came on light volume of 55.00 shares and a low average volume backdrop, so price action is sharp but fragile. Traders should note the upcoming earnings date on 02 Apr 2026 and the stock’s tiny market cap of €570,696.00 before positioning.

Intraday surge in PA8.F stock

Paion AG (PA8.F) traded at €0.08 after an intraday rise of 87.79% versus the previous close of €0.04. The advance is flagged in market feeds and local coverage, see Investing.com coverage. Volume was 55.00 versus an average of 2,162.00, underlining a low-liquidity rally.

The gap and close price are notable, but the trade size shows retail or block activity, not broad institutional buying. We treat the spike as a short-term event until confirmed by stronger volume or company news.

Price action, averages and market context

PA8.F opened at €0.08, matching the day high and day low. The 50-day average is €0.02 and the 200-day average is €0.01, so the current price sits above both short and long averages. The year high is €0.18 and the year low is €0.00, giving a wide trading band.

The stock is listed on XETRA in Germany, and market cap stands at €570,696.00 with 7,133,700.00 shares outstanding. That small market cap increases volatility and the impact of even modest orders.

Fundamentals and valuation for Paion AG (PA8.F)

Paion AG operates in Healthcare, focused on anesthesia and critical care products. Key metrics show a negative PE (N/A EPS) and a low price-to-sales ratio of 0.02. Gross profit margin is strong at 94.10%, but net margin is negative at -1.74%, reflecting limited profitability.

Operating cash flow and free cash flow per share are reported as N/A, and the balance sheet details show minimal scale. The next earnings announcement is scheduled for 02 Apr 2026, which could provide clarity on revenue or cost trends.

Technicals, signals and Meyka AI stock grade

Technical indicators are mixed. RSI sits at 50.46, neutral; CCI reads 192.15, flagged overbought; Bollinger middle band is €0.07 with an upper band at €0.11. Price momentum is quick but volatility measures show ATR €0.02.

Meyka AI rates PA8.F with a score out of 100: 62.48 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade signals balanced upside potential but elevated risk due to low liquidity.

Forecasts, price targets and Meyka AI outlook

Meyka AI’s forecast model projects a short-term monthly level of €0.07 versus the current €0.08, implying a model-based downside of -12.50%. Forecasts are model-based projections and not guarantees.

We present a scenario range: a conservative near-term target €0.05 and an optimistic tactical target €0.15 if volume and positive news follow. These targets reflect the stock’s tiny float and potential headline-driven moves.

Risks, catalysts and trading strategy

Key risks are extremely low liquidity, tiny market cap of €570,696.00, and lack of current EPS data. A single block trade can move the price materially. Upcoming earnings on 02 Apr 2026 and any corporate updates are primary catalysts.

For active traders we suggest small size exposure, tight stops and watching for confirmation with volume above the 2,162.00 average. Long-term investors should demand clearer fundamentals and consistent cash-flow metrics before adding PA8.F stock to portfolios.

Final Thoughts

PA8.F stock delivered a sharp intraday gain to €0.08 on 24 Mar 2026, but the rise rests on very light volume. Fundamentals show a specialty healthcare firm with strong gross margins but negative net profit and no published EPS. Technicals are mixed and the CCI flags short-term overbought conditions. Meyka AI rates PA8.F with a score out of 100: 62.48 (Grade B, HOLD). Meyka AI’s forecast model projects a monthly level of €0.07, implying -12.50% vs the current price; forecasts are model-based projections and not guarantees. Short-term traders may find tactical opportunities toward the year high €0.18, but liquidity risk and the small market cap of €570,696.00 argue for strict risk controls. We recommend monitoring volume, the 50-day average €0.02, and the earnings update on 02 Apr 2026 before increasing exposure. For more live context see our PA8.F page on Meyka and the market feed on Investing.com: Meyka stock page PA8.F and Investing.com coverage.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.